Big pharma outlines deal-making initiatives at ERBI
This article was originally published in Scrip
Executive Summary
Deal-making has become an important survival strategy for small to medium-sized biotechnology companies in the current credit squeeze, and pharmaceutical companies are keen to take advantage of the early-stage collaborative drug discovery and development opportunities on offer, delegates heard at the 11th annual ERBI Cambridge BioPartnering Exchange conference, which is taking place in the UK this week.